Literatur
- 1
Angus R, Reagon R, Cheesbrough A.
Short-acting beta 2-agonist and oral corticosteroid use in asthma
patients prescribed either concurrent beclomethasone and long-acting
beta 2-agonist or salmeterol/fluticasone propionate combination.
Int J Clin Pract.
2005;
59
156-162
- 2
Blais L, Suissa S, Boivin J -F, Ernst P.
First treatment with inhaled
corticosteroids and the prevention of admissions to hospital for
asthma.
Thorax.
1998;
53
1025-1029
- 3
Buhl R, Berdel D, Criée C -P. et al .
Leitlinie zur Diagnostik
und Therapie von Patienten mit Asthma.
Pneumologie.
2006;
60
139-163
- 4
Castle W, Fuller R, Hall J, Palmer J.
Serevent nationwide surveillance study:
comparison of salmeterol with salbutamol in asthmatic patients who
require regular bronchodilator treatment.
Brit Med J.
1993;
306
1034-1037
- 5
Deutsche Atemwegsliga und
Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin
e. V., Hrsg .
Leitlinie zur Diagnostik und
Therapie von Patienten mit Asthma.
Pneumologie.
2006;
60
139-183
- 6
Gillissen A, Berdel D, Buhl R. et
al .
ß2-Sympathomimetika: Gefahren in der Asthmatherapie?
Lehren aus der SMART-Studie. Eine Stellungnahme der Deutschen Atemwegsliga.
Dtsch Med Wochenschr.
2007;
132
33-39
- 7
Huchon H, Magnussen H, Chuchalin A, Dymek L, Gonod F B, Bousquet J.
Lung function and asthma
control with beclomethasone and formoterol in a single inhaler.
Respir Med.
2009;
103
41-49
- 8
Inman W H, Adelstein A M.
Asthma mortality
and pressurised aerosols.
Lancet.
1969;
2
693
- 9 IQWIG (Institut für
Qualität und Wirtschaftlichkeit im Gesundheitswesen) .Fixe Kombinationen aus Kortikosteroiden
und lang wirksamen Beta-2-Rezeptoragonisten
zur inhalativen Anwendung bei Patienten mit Asthma bronchiale – Ergänzungsauftrag.
IQWiG-Berichte – Jahr: 2008 Nr. 38 Abschlussbericht. www.iqwig.de/download/A07 – 01_Abschlussbericht_ICS_LABA_Fixkombinationen_bei_Asthma_bronchiale_Ergaenzungsauftrag.pdf
(Zugriff am 7.1.2009).
- 10
Kuehn B M.
FDA panel: Ban 2 popular asthma drugs.
JAMA.
2009;
301
365-366
- 11
Lazarus S C, Boushey H A, Fahy J V. et al, Asthma Clinical Research Network for
the National Heart, Lung, and Blood Institute .
Long-acting beta2-agonist
monotherapy vs continued therapy with inhaled corticosteroids in
patients with persistent asthma: a randomized controlled trial.
JAMA.
2001;
285
2583-2593
- 12
Marceau C, Lemière C, Berbiche D, Perreault S, Blais L.
Persistence, adherence, and effectiveness of combination therapy
among adult patients with asthma.
J Allergy Clin Immunol.
2006;
118
574-581
- 13 National Heart Lung
and Blood Institute National Institutes of Health .Global
Strategy for Asthma Management and Prevention – updated Dezember
2008. www.ginasthma.com/Guidelineitem.asp??l1 = 2&l2 = 1&intId = 60.
(Zugriff am 2.1.2009).
- 14
Nationale Versorgungs-Leitlinie
Asthma.
Dt Ärztebl.
2005;
102
A2734-A2739
- 15
Nelson H S, Chapman K R, Pyke S D, Johnson M, Pritchard J N.
Enhanced synergy between fluticasone
propionate and salmeterol inhaled from a single inhaler versus separate
inhalers.
J Allergy Clin Immunol.
2003;
112
29-36
- 16
Nelson H S, Weiss S T, Bleecker E R, Yancey S W, Dorinsky P M. et al, SMART Study
Group .
The
Salmeterol Multicenter Asthma Research Trial: a comparison of usual
pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.
Chest.
2006;
129
15-26
- 17
Ni Chroinin M, Greenstone I R, Danish A. et al .
Long-acting beta2-agonists versus placebo
in addition to inhaled corticosteroids in children and adults with
chronic asthma.
Cochrane Database Syst Rev.
2005;
(4)
, CD005535
- 18
O’Connor R D, Rosenzweig J R, Stanford R H. et al .
Asthma-related
exacerbations, therapy switching, and therapy discontinuation: a
comparison of 3 commonly used controller regimens.
Ann
Allergy Asthma Immunol.
2005;
95
535-540
- 19
Pauwels R A, Löfdahl C G, Postma D S. et al .
Effect of inhaled
formoterol and budesonide on exacerbations of asthma. Formoterol
and Corticosteroids Establishing Therapy (FACET) International Study
Group.
N Engl J Med.
1997;
337
1405-1411
- 20
Rabe K F, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo U G.
Effect of budesonide
in combination with formoterol for reliever therapy in asthma exacerbations:
a randomised controlled, double-blind study.
Lancet.
2006;
368
744-753
- 21
Rosenhall L, Elvstrand A, Tilling B. et al .
One-year safety and efficacy of budesonide/formoterol
in a single inhaler (Symbicort Turbuhaler) for the treatment of
asthma.
Respir Med.
2003;
97
702-708
- 22
Sears M R, Taylor D R, Print C G. et al .
Regular inhaled beta-agonist treatment
in bronchial asthma.
Lancet.
1990;
336
1391-1396
- 23
Stoloff S W, Stempel D A, Meyer J, Stanford R H, Carranza R osenzweig JR.
Improved refill persistence with
fluticasone propionate and salmeterol in a single inhaler compared
with other controller therapies.
J Allergy Clin Immunol.
2004;
113
245-251
- 24
Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B.
Low-dose inhaled corticosteroids and the prevention of death
from asthma.
N Engl J Med.
2000;
343
332-336
- 25
Suissa S, Ernst P, Kezouh A.
Regular use of inhaled corticosteroids and the long term prevention
of hospitalisation for asthma.
Thorax.
2002;
57
880-884
- 26
Thier S L, Yu-Isenberg K S, Leas B F. et al .
In chronic disease, nationwide data
show poor adherence by patients to medication and by physicians
to guidelines.
Manag Care.
2008;
17
48-52, 55 – 57
Prof. Dr. med. Roland Buhl
III. Medizinische Klinik, Schwerpunkt Pneumologie, Klinikum
der Johannes Gutenberg-Universität Mainz
Langenbeckstraße
1
55131 Mainz
Phone: 06131/17-7270
Fax: 06131/17-5545
Email: r.buhl@3-med.klinik.uni-mainz.de
